A CRO Bid Defence Deck Should Show How You Handle Execution Risk, Not Why You Are Credible

1. The sponsor is buying down risk, and cost can only subtract

By the time a CRO reaches the bid defence meeting, it has already passed RFP scoring. Finalists are invited to defend their proposals in front of the sponsor's cross-functional team. The deck is therefore not an introduction. It is the place where the sponsor tests whether the proposal's assumptions survive questions.

The selection research is consistent on what sponsors weigh, and consistent on a trap. ISR's 2013 analysis of sponsor behaviour found that cost 'invariably' sat well down the list of stated selection drivers, behind therapeutic expertise, quality project managers and prior relationships. When ISR asked sponsors what rules a CRO out, however, high cost was the leading answer by a substantial margin. ISR's conclusion was that cost is unlikely to win a bid but can certainly lose one. A separate survey article reported that more than a third of CROs (38%) believed price was a fundamental selection measure for sponsors, while sponsors were far more likely than CROs to stress the project management team. CROs, on this evidence, over-model price and under-model the people who will run the study.

This evidence is dated. The ISR cost analysis is from 2013, and the survey article carries no publication year in the copy we could retrieve. ISR's more recent benchmarking (Phase II/III CRO study, reported June 2024) confirms that therapeutic expertise is valued whichever decision scenario applies, and that preferred provider agreements are used by 88% of large sponsors, 54% of mid-size sponsors and 16% of small sponsors. The 2024 data narrows the audience: at a large sponsor, you may be defending against an incumbent, not competing on a blank sheet.

The practical consequence is a change in the deck's opening. Credentials earn a place on the invitation, not in the first five minutes. The first slide should name the execution risks of this protocol, as the sponsor would list them, and state how the CRO has priced and staffed against each.

2. Feasibility slides should show where sites fail, not how many countries you cover

The country count is the most common feasibility visual and the least informative. A map with 18 shaded countries tells the sponsor where a CRO has a presence. It says nothing about how many of those sites will enrol.

The benchmark most decks reach for is also wrong. A metric presented at a small conference in 2000, based on interviews with clinical operations managers, held that 20% of investigative sites fail to enrol a single patient, 30% under-enrol, 30% meet target and 20% exceed it. It became a widely cited fact. When Tufts CSDD measured performance directly, using data from 10 pharmaceutical companies and two CROs covering nearly 16,000 sites in 151 trials run in 2008–2010, the distribution was different: 11% enrolled none, 37% under-enrolled, 39% met target and 13% exceeded it.

Table 1 sets the two side by side.

Table 1. Site enrolment performance: the rule of thumb versus the Tufts CSDD measurement (both dated)

Both columns sum to 100%.

The corrected picture changes what a feasibility slide should argue. Zero-enrolling sites are a smaller problem than the folklore implies. Under-enrolment is a larger one: more than a third of sites in a typical trial fall short. A bid defence slide that promises 'no dormant sites' is answering the wrong question. The credible slide shows a site-level funnel for this protocol (identified, selected, activated, enrolling, at target), states the assumed share at each stage, and says what the CRO will do about the under-enrolling band. Where the CRO's own past studies show where selected sites stalled, that history is stronger evidence than any benchmark.

The Tufts data is dated. We have not located a later Tufts CSDD update that replaces it, and the dated label should stay on the slide: 'Tufts CSDD, 2008–2010 trials'.

For design treatment of funnel and distribution charts, see our guide to clinical data visualisation.

3. The timeline slide has to admit slip

The headline Tufts finding is easy to misread. Nine in ten trials, 89%, meet their enrolment goals. But Tufts reported that reaching those goals typically meant nearly doubling the original timeline. An earlier CenterWatch study of several hundred sites reported that upwards of 90% of trials miss the timeline set in the study contract.

Both findings are dated, and CenterWatch's was sample-based rather than a census of trials. The direction is still clear enough to shape a slide. A single Gantt bar with a hard enrolment-complete date invites the sponsor's operations lead to ask what happens when it slips, and the CRO that has no answer on the page loses ground in the room.

The stronger treatment is a scenario band: planned, expected and stress-case enrolment completion, with the assumptions that separate them (screen-failure rate, site activation lag, competing studies). This does two things. It shows the sponsor that the CRO has priced against slip rather than against the optimistic case, and it turns a later change-order conversation into one already framed on the page. For structuring the argument before the data is final, the ghost deck method applies directly.

4. Oversight slides now have a regulatory template

The governance slide is usually an org chart. It should be a map of obligations.

Under 21 CFR 312.52, a sponsor may transfer any or all obligations to a CRO, but the transfer must be described in writing, and any obligation not covered by the written description is deemed not transferred. A CRO that assumes an obligation is subject to the same regulatory action as a sponsor for failing to meet it. That makes the scope-of-delegation slide a regulatory matter, not a courtesy. 'Full service' on a slide is not a description of obligations.

ICH E6(R3) sharpened the sponsor's side of the relationship. It reached ICH Step 4 on 6 January 2025, took effect in the EU on 23 July 2025, and FDA issued its own final guidance on 8 September 2025. The guideline now refers to 'service providers' rather than CROs, reflecting a wider set of organisations carrying out specific trial activities, and explicitly requires service providers to report to the sponsor any incident that could affect participants' rights or the reliability of trial results. Oversight, in R3, is a design decision: the sponsor is expected to define and document the basis for oversight in proportion to risk, not merely confirm that a contract exists. WCG's summary identifies a new sponsor-oversight section (3.9) and a provision on oversight of activities that are transferred and then subcontracted (3.6.10).

Table 2 translates those requirements into slide decisions. It is the part of this page that a competitor cannot copy without doing the same reading.

Table 2. From regulatory requirement to bid defence slide

5. Delegation and subcontractor scope belongs on a slide, not in the contract appendix

Sponsors who have read R3 will ask a question that predates it: who is actually doing this work? A CRO that answers in the room, from memory, has conceded the point. The same information on a slide, with named organisations, activities and oversight owners, makes the CRO look like the party that has already thought about the sponsor's inspection exposure.

The design discipline matters here. A subcontractor map is a dense object, and it belongs in the same visual family as the oversight table: one row per activity, columns for provider, scope, and the CRO owner. Leave out logos and keep columns aligned. A subcontractor slide designed to look reassuring and not to be read is the one that gets questions.

6. The team slide must prove the people in the room will run the study

The recurring complaint about bid defences is not about the deck. Laurie Halloran, writing in 2017, noted growing sponsor concern about the disconnect between the CRO's business development group and the clinical operations team that takes over after the meeting; some sponsors had dropped bid defences, and others were replacing them with workshops. The article is paywalled, so only its opening is verified. A later industry guide says most observers still consider a well-executed bid defence valuable. Both are dated and secondary; both point the same way.

If the recurring failure is a hand-off, the team slide should address it directly. Show the named project lead, clinical lead and data lead who will run the study, their overlap with the people presenting, and what portion of the proposed hours each person carries. That is more persuasive than a headshot grid. Sponsors weigh the project management team heavily, and the team slide is where the CRO shows the team is real.

7. Build the deck to be interrupted

A bid defence is, in the words of one sponsor-side guide, part presentation and mostly a forum for discussion, serving as a microcosm of how the partnership would work. That has an architectural consequence. A deck written to be presented straight through, at a fixed pace, breaks the first time the sponsor stops it.

The architecture that survives interruption has two layers. The first is a short core path: the risk framing slide, the site-level feasibility funnel, the timeline scenario band, the obligations map, the oversight table, the team slide, and a pricing slide that exposes the assumptions behind the number. The second is a prepared appendix of backup slides keyed to the questions each core slide is likely to draw: site selection logic, screen-failure assumptions, subcontractor oversight detail, change-order mechanics.

On the pricing slide, the evidence in section 1 is the reason to show assumptions and not only totals. If cost can lose a bid, the number must read as the consequence of the feasibility and staffing assumptions already on the page, not as an isolated figure.

Table 3 sets out the treatments that tend to fail beside the ones that hold up.

Table 3. Common treatments versus treatments that hold up under questioning

For a wider treatment of sponsor-facing deck design in pharma, see our guide to pharmaceutical presentation design.

8. What the evidence does not tell us

Three gaps should be stated plainly, because a page that claims more than the evidence supports would not survive the audience it is written for.

First, we found no primary data on whether slide design changes selection outcomes. The argument that these treatments help is a synthesis of selection research, enrolment benchmarking and regulation. It is a reasoned position, not a measured effect.

Second, we found no published win-rate data for bid defences. The trade guides describe the meeting; none quantify it.

Third, the benchmarks that carry this page are old. Tufts CSDD's enrolment distribution comes from trials run in 2008–2010. ISR's cost analysis is from 2013. We have not located newer figures that replace either, and the 2024 ISR benchmarking available publicly describes selection criteria and preferred provider use but not the non-award reasons. Where this page uses older figures, it labels them as such, and a sponsor reading it should treat them as the best available evidence, not current measurement.

On market size: the oft-quoted CRO market figures are scope-dependent. MarketsandMarkets projects $93.02 billion in 2026 and $140.32 billion by 2031 at an 8.6% CAGR, while other estimates range from roughly $48 billion for pharmaceutical CRO work only to about $100 billion for the full services market. The number is context for a CRO's own marketing. It has no place in a bid defence deck.

FAQ